Abiopharma

Phase 3 Data forIncyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

New Form 4 - Avidity Biosciences, Inc. Filed: 2025-06-12 AccNo: 0001599901-25-000129 Size: 7 KB

New Form 4 - Avidity Biosciences, Inc. Filed: 2025-06-12 AccNo: 0001599901-25-000127 Size: 7 KB

New Form 4 - Avidity Biosciences, Inc. Filed: 2025-06-12 AccNo: 0001599901-25-000125 Size: 7 KB

ResMed Inc. Daily Stock Update

New Form 4 - Avidity Biosciences, Inc. Filed: 2025-06-12 AccNo: 0001599901-25-000123 Size: 8 KB

New Form 4 - Black Diamond Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085676 Size: 35 KB

New Form 4 - Akero Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085674 Size: 9 KB

New Form 4 - Akero Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085673 Size: 5 KB

New Form 4 - Akero Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085672 Size: 5 KB

New Form 4 - Akero Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085671 Size: 5 KB

New Form 4 - Akero Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085667 Size: 8 KB

New Form 4 - Akero Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085670 Size: 5 KB

New Form 4 - Avidity Biosciences, Inc. Filed: 2025-06-12 AccNo: 0001599901-25-000121 Size: 7 KB

New Form 4 - Black Diamond Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0001415889-25-017058 Size: 5 KB